Microcap Ledger Pyxis Oncology, Inc. $PYXS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 83,408,050 [10-Q 2026-08-13]
What the company doesAI summary of filing
Pyxis Oncology is a clinical-stage oncology company developing micvotabart pelidotin (MICVO), an investigational antibody-drug conjugate that targets a fibronectin variant found in solid tumors. The company is conducting Phase 1 trials of MICVO as a monotherapy and in combination with pembrolizumab (KEYTRUDA) in patients with head and neck squamous cell carcinoma and other solid tumors, with preliminary clinical data showing response rates and disease control in heavily pre-treated patients. The company is pre-revenue and focused on advancing MICVO through clinical development to address unmet needs in difficult-to-treat cancers. [10-K 2026-03-23]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$48.62M | −$44.21M | $18.86M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $13.86M | −$79.62M | −$63.50M | $15.42M | [10-K 2026-03-23] |
| FY ended Dec 2024 | $16.15M | −$77.33M | −$57.67M | $19.47M | [10-K 2026-03-23] |
- Quarterly cash burn
- −$22.10M
- Cash runway Estimate
- ~2.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 59,465,729 | [10-Q 2024-11-12] |
| 2025-03-17 | 61,590,415 | [10-K 2025-03-18] |
| 2025-05-14 | 61,947,665 | [10-Q 2025-05-15] |
| 2025-08-13 | 62,018,135 | [10-Q 2025-08-14] |
| 2025-10-31 | 62,264,215 | [10-Q 2025-11-03] |
| 2026-03-20 | 62,831,246 | [10-K 2026-03-23] |
| 2026-05-08 | 63,355,482 | [10-Q 2026-05-14] |
| 2026-08-12 | 83,408,050 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-08-20; declared effective 2026-08-27 [S-3 2026-08-20]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Gordonmd Global Investments Lp | buy | 5,517,000 | — | [4 2026-10-02] |
| 2026-06-30 | Dupont Jakob | exercise | 35,000 | $1.60 | [4 2026-07-02] |
| 2026-06-30 | Dupont Jakob | sell | 35,000 | $3.06 | [4 2026-07-02] |
| 2026-03-24 | Wadhane Jitendra | grant | 109,461 | — | [4 2026-03-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | PRE 14A | Proxy statement |
| 2026-10-09 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-05 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-10-02 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-01 | 8-K | Material agreement entered; Other events |
| 2026-10-01 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-29 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-29 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-09 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-08 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-08-28 | 424B2 | Prospectus or prospectus supplement |
| 2026-08-20 | S-3 | Registration statement |
Alerts for $PYXS
Email me when Pyxis Oncology, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.